HER-3 Targeting Alters the Dimerization Pattern of ErbB Protein Family Members in Breast Carcinomas

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Dec 31

PMID 26716646

Citations 6

Authors

Michalis V Karamouzis

Georgia Dalagiorgou

Urania Georgopoulou

Afroditi Nonni

Michalis Kontos

Athanasios G Papavassiliou

Affiliations

Soon will be listed here.

Abstract

Breast carcinogenesis is a multi-step process in which membrane receptor tyrosine kinases are crucial participants. Lots of research has been done on epidermal growth factor receptor (EGFR) and HER-2 with important clinical results. However, breast cancer patients present intrinsic or acquired resistance to available HER-2-directed therapies, mainly due to HER-3. Using new techniques, such as proximity ligation assay, herein we evaluate the dimerization pattern of HER-3 and the importance of context-dependent dimer formation between HER-3 and other HER protein family members. Additionally, we show that the efficacy of novel HER-3 targeting agents can be better predicted in certain breast cancer patient sub-groups based on the dimerization pattern of HER protein family members. Moreover, this model was also evaluated and reproduced in human paraffin-embedded breast cancer tissues.

Citing Articles

Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway.

Siatis K, Giannopoulou E, Manou D, Sarantis P, Karamouzis M, Raftopoulou S Am J Physiol Cell Physiol. 2023; 325(3):C708-C720.

PMID: 37575061 PMC: 10625825. DOI: 10.1152/ajpcell.00199.2023.

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.

Alanazi S, Feroz W, Mishra R, Kilroy M, Patel H, Yuan L PLoS One. 2023; 18(5):e0285251.

PMID: 37200287 PMC: 10194889. DOI: 10.1371/journal.pone.0285251.

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis.

Ilie S, Bacinschi X, Botnariuc I, Anghel R Breast Cancer (Dove Med Press). 2018; 10:177-194.

PMID: 30538542 PMC: 6257362. DOI: 10.2147/BCTT.S175556.

Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.

Luhtala S, Staff S, Kallioniemi A, Tanner M, Isola J BMC Cancer. 2018; 18(1):1045.

PMID: 30367623 PMC: 6204010. DOI: 10.1186/s12885-018-4917-1.

Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization.

Magi S, Iwamoto K, Yumoto N, Hiroshima M, Nagashima T, Ohki R J Biol Chem. 2017; 293(6):2206-2218.

PMID: 29233889 PMC: 5808779. DOI: 10.1074/jbc.M117.778399.

References

Barros F, Powe D, Ellis I, Green A . Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology. 2010; 56(5):560-72. DOI: 10.1111/j.1365-2559.2010.03494.x. View

Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius K, Jarvius J . Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006; 3(12):995-1000. DOI: 10.1038/nmeth947. View

Cortes J, Fumoleau P, Bianchi G, Petrella T, Gelmon K, Pivot X . Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012; 30(14):1594-600. DOI: 10.1200/JCO.2011.37.4207. View

Wakui H, Yamamoto N, Nakamichi S, Tamura Y, Nokihara H, Yamada Y . Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014; 73(3):511-6. PMC: 3931937. DOI: 10.1007/s00280-014-2375-2. View

Yuste L, Montero J, Esparis-Ogando A, Pandiella A . Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res. 2005; 65(15):6801-10. DOI: 10.1158/0008-5472.CAN-04-4023. View

Garrett J, Arteaga C . Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther. 2011; 11(9):793-800. PMC: 3230295. DOI: 10.4161/cbt.11.9.15045. View

Chakrabarty A, Rexer B, Wang S, Cook R, Engelman J, Arteaga C . H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene. 2010; 29(37):5193-203. PMC: 2945381. DOI: 10.1038/onc.2010.257. View

Mina M, Magi S, Jurman G, Itoh M, Kawaji H, Lassmann T . Promoter-level expression clustering identifies time development of transcriptional regulatory cascades initiated by ErbB receptors in breast cancer cells. Sci Rep. 2015; 5:11999. PMC: 4503981. DOI: 10.1038/srep11999. View

Karamouzis M, Grandis J, Argiris A . Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007; 298(1):70-82. DOI: 10.1001/jama.298.1.70. View

10.

Dey N, Williams C, Leyland-Jones B, De P . A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 2015; 7(4):733-50. PMC: 4455348. View

11.

Haas S, Gevensleben H, Rabstein S, Harth V, Pesch B, Bruning T . Expression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers. Oncol Rep. 2009; 21(2):299-304. View

12.

Gala K, Chandarlapaty S . Molecular pathways: HER3 targeted therapy. Clin Cancer Res. 2014; 20(6):1410-6. PMC: 3977203. DOI: 10.1158/1078-0432.CCR-13-1549. View

13.

Shankaran H, Zhang Y, Tan Y, Resat H . Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3. PLoS Comput Biol. 2013; 9(8):e1003201. PMC: 3749947. DOI: 10.1371/journal.pcbi.1003201. View

14.

Haskins J, Nguyen D, Stern D . Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Sci Signal. 2014; 7(355):ra116. PMC: 4648367. DOI: 10.1126/scisignal.2005770. View

15.

Menendez J, Mehmi I, Lupu R . Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol. 2006; 24(23):3735-46. DOI: 10.1200/JCO.2005.04.3489. View

16.

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

17.

Khurana A, Gonzalez-Guerrico A, Lupu R . Heregulin in breast cancer: old story, new paradigm. Curr Pharm Des. 2013; 20(30):4874-8. DOI: 10.2174/1381612819666131125151519. View

18.

van Dieck J, Schmid V, Heindl D, Dziadek S, Schraeml M, Gerg M . Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation. Chem Biol. 2014; 21(3):357-68. DOI: 10.1016/j.chembiol.2013.12.018. View

19.

Garrett J, Sutton C, Kuba M, Cook R, Arteaga C . Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res. 2012; 19(3):610-9. PMC: 3563762. DOI: 10.1158/1078-0432.CCR-12-2024. View

20.

Nishio M, Horiike A, Murakami H, Yamamoto N, Kaneda H, Nakagawa K . Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer. 2015; 88(3):275-81. DOI: 10.1016/j.lungcan.2015.03.010. View